David S. Johnson BA, BS, PhD, MBA

Dr. Johnson is an inventor, entrepreneur, and expert in single-cell genomics with a track record of bringing new medical technologies to market. As Founder and CEO of GigaGen, Dr. Johnson has raised >$65 million in non-dilutive and partnership capital to build patented, world-leading technologies for immune repertoire genomics. GigaGen is now leveraging this technology for the development of novel antibody therapies for oncology and immunology indications. Previously, Dr. Johnson was among the founding members and COO of Natera (NASDAQ: NTRA).

At Natera, Dr. Johnson was responsible for all clinical operations, laboratory research, clinical studies, and clinical product development. Prior to Natera, he was the ENCODE Project Director at the Stanford Human Genome Center. Dr. Johnson holds a BS in Biology from Duke University, a PhD in Genetics from Stanford University, and an MBA from the Haas School of Business at the University of California, Berkeley.